About the Company
nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NRIX News
Nurix Therapeutics gets grant for degradation of BTK using compound of formula (a)
Discover the groundbreaking patent by Nurix Therapeutics for compounds targeting and degrading BTK, offering hope for treating cancer, autoimmune diseases, and more. Explore the potential therapeutic ...
Nurix Therapeutics files patent for bifunctional compounds for hpk1 degradation in disease treatment
Discover how Nurix Therapeutics' patent for bifunctional compounds targeting HPK1 activity offers a groundbreaking method for treating diseases, including cancer. Learn more about this innovative ...
Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting
Presentation highlights Nurix’s innovation and leadership in targeted protein modulation, including ligase inhibitionUnique mechanism of action, ...
NRIX Oct 2024 12.500 call
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...
Structures of new cancer drug candidates revealed
The cancer immunotherapy talks continued with Frederick Cohen presenting NX-1607. This drug candidate was made to target CBL-B, an immune checkpoint protein that limits the ability of T cells to ...
InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
InflaRx N.V. (IFRX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.18 per share a year ago. These figures are ...
New Haven-based BioXcel Therapeutics announces $25M offering
BioXcel Therapeutics Inc., a New Haven-based biopharmaceutical company that uses artificial intelligence to develop medicines ...
NeuBase Therapeutics sets shareholder meeting on dissolution plan
NeuBase Therapeutics will hold a special shareholder meeting May 13 to approve a plan to liquidate and dissolve the ...
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Kymera is advancing into Phase 2 with Sanofi, which could validate protein deg approach, open up multi-billion dollar market ...
Praxis gains after mid-stage data for epilepsy candidate
Praxis Precision Medicines (PRAX) stock surges as its anti-seizure drug shows potential in treating epilepsy patients with photo paroxysmal response. Read more here.
Rakovina Therapeutics Announces Strategic Pivot to AI
Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of novel DNA-damage ...
Loading the latest forecasts...